

## PRESS RELEASE



### **BONESUPPORT PRESS RELEASES - 2012**

**December 14, 2012**

BONESUPPORT™ features on a billboard in Times Square NYC USA announcing the Red Herring Global Top 100 Award

**December 6, 2012**

[BONESUPPORT Selected As A 2012 Red Herring Top 100 Global](#)

**September 5, 2012**

[BONESUPPORT™ ANNOUNCES EXCLUSIVE SUPPLY AND DISTRIBUTION AGREEMENT WITH BIOMET, INC. FOR BONESUPPORT™'S PROPRIETARY CERAMENT™ | BONE VOID FILLER - Agreement Covers Distribution Rights of CERAMENT in United States and Canada](#)

**July 2, 2012**

[BONESUPPORT Names Mr. Offer Nonhoff As New Chief Financial Officer](#)

**June 19, 2012**

[BONESUPPORT Closes Second Tranche of Funding](#)

**May 1, 2012**

[BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award](#)

**April 17, 2012**

BONESUPPORT™ appoints Andreas Muchowski to VP of sales Germany

**April 4, 2012**

[CEO 100 Day Report - Increasing Sales of CERAMENT™ through New Distribution Channels Among Top Priority](#)

**March 27, 2012**

[BONESUPPORT Launches New Web Site](#)

**January 2, 2012**

[Fredrik Lindberg is this year's Ideon prizewinner](#)

## Notes to Editor

### About BONESUPPORT™

BONESUPPORT AB has developed CERAMENT™ as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT™ |BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT™ |BVF is commercially available in the U.S., EU, S.E. Asia and the Middle East.

CERAMENT™'s distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT™ |G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT™ |G and CERAMENT™ V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT™ |G and CERAMENT™ V are available in the EU.

BONESUPPORT AB was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT's mission is to bring people with bone and joint diseases back to an active life. The company is based in Lund, Sweden.

*BONESUPPORT™ is a registered trademark.*

## Contact Information

### **Citigate Dewe Rogerson**

David Dible, Andrea Bici, Mark Swallow

+44 (0)20 7282 2949/1050/2948

[bonesupport@citigatedr.co.uk](mailto:bonesupport@citigatedr.co.uk)